Bethesda-based Sucampo Pharmaceuticals’ second quarter net income jumped $29.9 million, or 71 cents per share, up from $13.9 million or 39 cents during the same quarter the previous year, the company announced.
The company said its cash and investments totaled $135 million at the end of the quarter, up from $86.5 million at the end of this past year. The increases reflected “continuing acceptance” of the company’s Amitza drug to treat chronic constipation in adults, company founder and CEO Dr. Ryuki Ueno said in a statement.
